Tags : Novel Biotherapies

Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to

Shots: The companies signed a multi-year, multifaceted collaboration to develop novel Ab to treat & prevent various diseases including oncology and immunology The collaboration leverages H2L2 Harbour Mice platform to generate mAb against SARS CoV 2 – COVID-19 and allow HBM to access Mount Sinai’s research-driven from its clinical practices The collaboration demonstrated HBM’s dedication […]Read More